Anavex Life Sciences Highlights Oral Alzheimer's Drug Blarcamesine, Precision Strategy at JPM Conference [Yahoo! Finance]
Anavex Life Sciences Corp. (AVXL)
NASDAQ:AMEX Investor Relations:
anavex.com/share-data
Company Research
Source: Yahoo! Finance
weeks (up to 49.8% in a pre-specified population) with a “very solid” safety profile and biomarker signals including reduced brain atrophy and effects on Aß42 plasma ratio. Anavex is pursuing a precision-medicine strategy: patients with sigma-1 wild-type and COL24A1 wild-type genotypes showed especially large effects (84.7% benefit on ADAS-Cog13 and 75.2% on CDR-SB at 30 mg), supporting targeted genetic subgroup approaches. The company is engaging regulators (seeking an EMA re-examination in Q1), reports about $120 million cash with 3 years of runway and no debt, and plans to advance a broader CNS pipeline including Parkinson's disease dementia, Rett syndrome, Fragile X and Anavex 3-71. Interested in Anavex Life Sciences Corp.? Here are five stocks we like better. Short-Squeeze Target Anavex Life Sciences Gains Traction Anavex Life Sciences (NASDAQ:AVXL) outlined its strategy to develop oral, precision-medicine therapies for central nervous system (CNS) diseases during a pre
Show less
Read more
Impact Snapshot
Event Time:
AVXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVXL alerts
High impacting Anavex Life Sciences Corp. news events
Weekly update
A roundup of the hottest topics
AVXL
News
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s DiseaseGlobeNewswire
- INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the FirmPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXLPR Newswire
- Anavex Life Sciences Appoints Senior Vice President Global Head of NeurologyGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXLGlobeNewswire
AVXL
Earnings
- 11/25/25 - Beat
AVXL
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 11/25/25 - Form 10-K
- AVXL's page on the SEC website